Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks - Takeaways - MDSpire

Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks

Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development

  • July 23, 2026

  • 8 min

Share

  • 1

    CAR T therapies are complex and heterogeneous, requiring precise single-cell analytical data to ensure safety and efficacy.

  • 2

    Mission Bio's Tapestri platform enables single-cell analysis of vector copy number, revealing dangerous outliers missed by bulk methods.

  • 3

    Single-cell VCN profiling can detect high-risk cells with VCN >5, which are associated with increased genotoxicity and oncogenesis.

  • 4

    Bulk methods like ddPCR obscure cellular heterogeneity, potentially masking critical safety risks in CAR T products.

  • 5

    Single-cell multiomics links genotype and phenotype, providing comprehensive insights into the quality and functionality of CAR T therapies.

Original Source(s)

Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks

  • July 23, 2026

Related Content

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
This Week's CGT News: World's First Solid Tumor CAR T Approved in China 

  • June 30, 2026

  • 6 min